Continuous Adductor Canal BlockNCT06802419
Effect of Continuous Adductor Canal Block Versus Continuous Adductor Canal Block With Additional Infiltration Between The Popliteal Artery and Capsule of The Knee (IPACK) After Arthroscopic Knee Surgeries
A study testing Continuous adductor canal block and Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule in people with Continuous Adductor Canal Block and Infiltration Between The Popliteal Artery and Capsule of The Knee, run by Ain Shams University at 1 site in Egypt.
Trial summary
This study aims to evaluate the effect of Continuous Adductor Canal Block only versus adding posterior knee block, known as the Infiltration between the Popliteal Artery and Capsule of the Knee (IPACK) block with Continuous Adductor Canal Block (CACB) after arthroscopic knee surgeries. Read more about this study
- Who is it for?
- Ages 21 to 65 years
- Conditions the study is for
- Continuous Adductor Canal Block, Infiltration Between The Popliteal Artery and Capsule of The Knee, Arthroscopic Knee Surgeries
- What is being tested?
- Continuous adductor canal block and Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteEgypt
- Study dates
- 30 Jan 2025to 1 Oct 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age from 21 to 65 years.
- Both sexes.
- American Society of Anesthesiologists (ASA) Physical Status Class I to II.
- Patients with successful spinal anesthesia.
- Patients scheduled for elective arthroscopic knee surgery for anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) repair.
Who cannot join
- Declining to give written informed consent.
- History of allergy to the medications used in the study.
- Contraindications to regional anesthesia (including coagulopathy and local infection).
- Polytrauma patients having lower limb fractures.
- Patients with pre-existing myopathy or neuropathy on the operating limb.
- Patients with diabetes mellitus.
Show all 9Show fewer
- Psychiatric disorder.
- Morbid obesity [body mass index (BMI) > 45kg/m2].
- Complicated Surgery.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Ain Shams University
Cairo, 11591
Nada E Hussein, Master, 00201112449418, Nadahussein@med.asu.edu.eg
Mohamed H Shokier, MD
About this study
Official title: A Comparative Study Between the Effect of Continuous Adductor Canal Block Versus Continuous Adductor Canal Block With Additional Infiltration Between The Popliteal Artery and Capsule of The Knee (IPACK) After Arthroscopic Knee Surgeries
This study aims to evaluate the effect of Continuous Adductor Canal Block only versus adding posterior knee block, known as the Infiltration between the Popliteal Artery and Capsule of the Knee (IPACK) block with Continuous Adductor Canal Block (CACB) after arthroscopic knee surgeries.
Read the detailed description
Enhanced recovery after arthroscopic knee surgery is gaining popularity in orthopedic surgeries. Motor preservation with adequate analgesia has become the optimal postoperative goal, enabling earlier physical therapy, faster recovery, and early hospital discharge. Spinal anesthesia for knee arthroscopy has favorable outcome effects compared with general anesthesia. The positive physiological effects of the provided sympathetic blockade with less blood loss, increased leg blood flow, and better initial pain relief explain this.
An ideal nerve block that targets the sensory nerves and spares the motor function can facilitate early ambulation and rehabilitation, a major goal for patients undergoing arthroscopic knee surgery.
A novel technique for posterior knee block, known as the infiltration between the popliteal artery and capsule of the knee (IPACK) block combined with continuous adductor canal block (CACB) would reduce opioid requirements.
- Conditions
- Continuous Adductor Canal Block, Infiltration Between The Popliteal Artery and Capsule of The Knee, Arthroscopic Knee Surgeries
- Being tested
- Continuous adductor canal block, Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous adductor canal blockOther
Patients will receive continuous adductor canal block.
Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and CapsuleOther
Patients will receive Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule of The Knee
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Experimental | Patients will receive continuous adductor canal block. Receives: Other: Continuous adductor canal block |
| Group 2 | Experimental | Patients will receive Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule of The Knee Receives: Other: Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule |
What is being measured
The primary outcome is the main question the study is designed to answer.
Degree of pain
The degree of pain will be assessed using the Visual Analogue Scale (VAS). VAS score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. No pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm).
Measured: 24 hours postoperatively
Secondary outcomes (4)
Total Nalbuphine consumption
Rescue analgesia will be given when VAS score ≥ 30 mm, in the form of IV injection of 10 mg Nalbuphine. Followed by reassessment of pain after 10 minutes, a second dose of Nalbuphine will be given if still VAS score ≥ 30 mm.
Measured: 24 hours postoperatively
Straight leg rise
Straight leg rise (SLR) will be recorded.
Measured: 24 hours postoperatively
Range of motion
Range of motion (ROM) will be recorded
Measured: 24 hours postoperatively
Rate of complications
Rate of complications like falling will be recorded
Measured: 24 hours postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jan 2025
- Study start30 Jan 2025
- Primary completion1 Oct 2025 (estimated)
- Study completion1 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Continuous Adductor Canal BlockStudies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nada Ezzat, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06802419
- Sponsor's protocol ID
- FMASU MD134/2024
- Status last verified
- Jan 2025
- First submitted
- 21 Jan 2025
- Last updated
- 31 Jan 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 31 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Comparative Study Between the Effect of Continuous Adductor Canal Block Versus Continuous Adductor Canal Block With Additional Infiltration Between The Popliteal Artery and Capsule of The Knee (IPACK) After Arthroscopic Knee Surgeries
- ClinicalTrials.gov ID
- NCT06802419
- Acronym / sponsor ID
- FMASU MD134/2024
- Conditions
- Continuous Adductor Canal Block, Infiltration Between The Popliteal Artery and Capsule of The Knee, Arthroscopic Knee Surgeries
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 30 Jan 2025 (actual)
- Primary completion
- 1 Oct 2025 (estimated)
- Study completion
- 1 Oct 2025 (estimated)
- First posted
- 31 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the effect of Continuous Adductor Canal Block only versus adding posterior knee block, known as the Infiltration between the Popliteal Artery and Capsule of the Knee (IPACK) block with Continuous Adductor Canal Block (CACB) after arthroscopic knee surgeries.
Detailed description
Enhanced recovery after arthroscopic knee surgery is gaining popularity in orthopedic surgeries. Motor preservation with adequate analgesia has become the optimal postoperative goal, enabling earlier physical therapy, faster recovery, and early hospital discharge. Spinal anesthesia for knee arthroscopy has favorable outcome effects compared with general anesthesia. The positive physiological effects of the provided sympathetic blockade with less blood loss, increased leg blood flow, and better initial pain relief explain this.
An ideal nerve block that targets the sensory nerves and spares the motor function can facilitate early ambulation and rehabilitation, a major goal for patients undergoing arthroscopic knee surgery.
A novel technique for posterior knee block, known as the infiltration between the popliteal artery and capsule of the knee (IPACK) block combined with continuous adductor canal block (CACB) would reduce opioid requirements.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1 | Experimental | Other: Continuous adductor canal blockPatients will receive continuous adductor canal block. |
| Group 2 | Experimental | Other: Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and CapsulePatients will receive Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule of The Knee |
Who may qualify
- Ages
- 21 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age from 21 to 65 years.
- Both sexes.
- American Society of Anesthesiologists (ASA) Physical Status Class I to II.
- Patients with successful spinal anesthesia.
- Patients scheduled for elective arthroscopic knee surgery for anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) repair.
Key exclusion criteria (9 listed)
- Declining to give written informed consent.
- History of allergy to the medications used in the study.
- Contraindications to regional anesthesia (including coagulopathy and local infection).
- Polytrauma patients having lower limb fractures.
- Patients with pre-existing myopathy or neuropathy on the operating limb.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous adductor canal blockPatients will receive continuous adductor canal block. | Other | Group 1 |
| Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and CapsulePatients will receive Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule of The Knee | Other | Group 2 |
Primary outcome
Degree of pain
Time frame: 24 hours postoperatively
The degree of pain will be assessed using the Visual Analogue Scale (VAS). VAS score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. No pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm).
4 secondary outcomes
Total Nalbuphine consumption
Time frame: 24 hours postoperatively
Straight leg rise
Time frame: 24 hours postoperatively
Range of motion
Time frame: 24 hours postoperatively
Rate of complications
Time frame: 24 hours postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jan 2025.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Continuous Adductor Canal Block
Not yet recruiting
Continuous Adductor Canal Block (CACB) Combined With İnfiltration Between the Popliteal Artery and Capsule of the Knee (iPACK) Block vs Continuous Adductor Canal Block Alone After Total Knee Arthroplasty
Total Knee Arthroplasty, Postoperative Pain
Active, not recruiting
Enhanced Recovery After Major Surgery and Chronic Pain for Total Knee Arthroplasty
Chronic Pain, Opioid Use
Not yet recruiting
Migration Rate for Continuous Adductor Canal Block Catheters After Primary Total Knee Arthroplasty Surgery: a Comparison Between Two Insertion Techniques
Arthroplasty Replacement, Knee, Anesthesia Conduction
Not yet recruiting
sACB vs cACB in TKA
Arthroplasty, Replacement
Recruiting
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
Anesthesia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Continuous adductor canal block and Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule in people with Continuous Adductor Canal Block and Infiltration Between The Popliteal Artery and Capsule of The Knee, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 31 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nada E Hussein, Master (00201112449418, Nadahussein@med.asu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Degree of pain (time frame: 24 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jan 2025.